In the TRK inhibition field, adding crizotinib (with activity against METy) to TRK inhibition with selitrectinib led to the control of cancer progression driven by emerging MET amplification after entrectinib use not controlled by monotherapy with selitrectinib [51]. This evidence concerns the gene MET and cancer.